Menu

Home / For Visitors / 2025 Exhibitor Product / Investigating the efficacy and mechanisms of rosoxacin in treating metabolic dysfunction-associated steatotic liver disease

Investigating the efficacy and mechanisms of rosoxacin in treating metabolic dysfunction-associated steatotic liver disease

Category: Pharmaceutical

Exhibitor: NATIONAL YANG MING CHIAO TUNG UNIVERSITY

Booth No: N327A

Characteristic

Non-alcoholic fatty liver disease (NAFLD) is a common chronic liver disease with only one FDA-approved drug, leaving significant unmet treatment needs. In collaboration with Professor Jinn-Moon Yang’s lab, the anti-inflammatory drug Rosoxacin was found to effectively reduce hepatic fat accumulation and alleviate NASH features in cell and mouse models.

Other Products

Products you may be interested in

Highest Rated Products

TOP